I'm a Pathologist. Do This When Ozempic & Mounjaro "Stop Working." (Weight Loss Plateau Explained)

Episode #4

Your Ozempic, Wegovy, Mounjaro or Zepbound "stopped working"? A flat scale doesn't mean the drug failed. I'm a pathologist, and in this episode I walk through what the trials show about the weight loss plateau, plus 4 questions to bring to your prescriber.

In the 4-year semaglutide trial, weight held about 10% elow where people started, as long as they stayed on the drug. The line goes flat where the drug's effect meets a smaller body that burns less energy. That's physiology, and it happens to everyone who loses weight.

What I cover:
Why the scale can stop while the drug is still working
Your fat cells under the microscope: they shrink, but the number stays about the same
The 3 kinds of plateau (dose, drug, and life after the drug) and why each one is a different conversation with your prescriber
5 things people try at a plateau, graded
Where retatrutide's "no plateau" headline came from (16:41)
How resistance training cut the muscle share of weight lost to 17.5%

Chapters
00:00 "I think it stopped working"
00:43 Three people, three scales
02:22 The graph: Ozempic, Zepbound, and the 4-year trial
03:41 Why your friend's weight loss curve looks different
05:02 The bucket: why every weight loss plateau happens
07:42 Your metabolism after weight loss (adaptive thermogenesis)
09:32 Your fat cells under the microscope
11:42 5 things people try at a plateau, graded
14:18 Maria: Mounjaro or Zepbound dose and tolerability
15:29 James: top-dose Ozempic or Wegovy, is there a different drug
16:41 Retatrutide and the "no plateau" press release
18:56 Denise: weight regain after the drug stops
20:07 Muscle loss: what the weight you lose is made of
21:46 The hardest fact
22:33 What I'd do this week: 4 questions for your prescriber
23:37 Where I land

The GLP-1 Method: 90 days of short daily videos on protein, muscle, sleep and how you eat. Current cohort dates and the free waitlist: getuninflamed.com
Watch on YouTube: @draminhedayat

References (checked on PubMed and the Lilly and FDA sites, September 2026)
1. Wilding JPH et al. STEP 1. N Engl J Med 2021;384:989-1002.
2. Wilding JPH et al. STEP 1 extension. Diabetes Obes Metab 2022;24:1553-1564.
3. Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022;387:205-216.
4. Ryan DH et al. SELECT weight outcomes. Nat Med 2024;30:2049-2057.
5. Aronne LJ et al. SURMOUNT-5. N Engl J Med 2025;393:26-36. Lilly funded, open-label.
6. Rubino D et al. STEP 4. JAMA 2021;325:1414-1425.
7. Hall KD. Physiology of the weight-loss plateau. Obesity 2024;32:1163-1168.
8. Leibel RL et al. N Engl J Med 1995;332:621-628.
9. Fothergill E et al. Obesity 2016;24:1612-1619 (n=14).
10. Spalding KL et al. Nature 2008;453:783-787.
11. Eisa N, Barood O. Diabetes Obes Metab 2026;28:4818-4827.
12. Lilly release, May 21, 2026, TRIUMPH-1 (company data).
13. Lilly release, March 19, 2026, TRANSCEND-T2D-1.
14. Bajaj HS et al. TRANSCEND-T2D-1. Lancet 2026;407:2402-2413.
15. FDA: concerns with unapproved GLP-1 drugs.
16. Nauck MA et al. Diabetes 2011;60:1561-1565.

Disclaimer: This episode is education, not medical advice, and it doesn't create a physician-patient relationship. Don't start, stop or change any medication because of an episode. Those decisions belong with you and your own physician. Maria, James and Denise are composites to protect patient identity. I'm an independent educator with no sponsor for this episode and no financial relationship with any drug maker, compounding pharmacy or peptide seller.